Comprehensive Cancer Centers shares what Radioisotope Therapy is, how the practice’s caregivers use the technology and the benefits it can have for patients.
Comprehensive Cancer Centers is driven by a constant search for treatments that destroy cancer cells while minimizing damage to healthy tissue. One of the most innovative and rapidly advancing approaches is targeted alpha and beta therapy, collectively known as radioisotope therapy or radiopharmaceutical therapy. Different from traditional external beam radiation, which delivers high-energy X-rays or gamma rays from outside the body through healthy tissue to reach a tumor, radioisotope therapy attacks cancer from within.
By attaching a radioactive isotope to a carrier molecule that selectively seeks out cancer cells, physicians can deliver a concentrated dose of radiation directly to the tumor. Understanding radioisotope therapy involves exploring the physics behind radioactive decay, the mechanisms of cellular targeting, its expanding clinical applications, and the specialized systems required to deliver these treatments safely.
At the heart of radioisotope therapy is the science of unstable atoms. Radioisotopes contain an imbalance of protons and neutrons within their nuclei, making them unstable. To regain stability, they undergo radioactive decay, a natural process in which energy and subatomic particles are released. In medicine, these emitted particles are used to damage the DNA of cancer cells, preventing them from reproducing and ultimately triggering apoptosis, or programmed cell death.
Types of Radiation for Radioisotope Therapy
Targeted radioisotope therapy primarily uses two forms of radiation: beta particles and alpha particles. Beta particles are fast-moving electrons or positrons released from the nucleus of a decaying atom. Because they have relatively little mass and carry a single positive or negative charge, they can travel approximately one to ten millimeters through tissue. This limited range creates an important bystander effect, allowing radiation to destroy not only the cancer cell that captures the radiopharmaceutical but also neighboring tumor cells that may not express the same target. Common beta-emitting isotopes used in clinical practice include Iodine-131, Lutetium-177, and Yttrium-90.
Alpha particles behave quite differently. They consist of two protons and two neutrons—the same structure as a helium nucleus—and are much heavier than beta particles. Their large mass and double positive charge produce extremely high linear energy transfer, allowing them to release tremendous destructive energy over an exceptionally short distance, typically less than one hundred micrometers, or only a few cell widths. When an alpha particle strikes DNA, it creates dense double-stranded breaks that cells are rarely able to repair. This highly localized effect makes alpha-emitting isotopes such as Actinium-225 and Radium-223 exceptionally effective against microscopic metastatic disease while minimizing damage to nearby healthy tissue.
The effectiveness of radioisotope therapy depends entirely on precise cellular targeting. Simply injecting radioactive material into the bloodstream would expose healthy tissues throughout the body to unnecessary radiation. Instead, each radioisotope is attached to a specialized carrier molecule that naturally seeks receptors found in unusually high numbers on cancer cells. These carriers may be monoclonal antibodies, small peptides, or chemical compounds that mimic substances the tumor uses for growth and survival.
The radioactive isotope is connected to its carrier using a specialized molecular structure known as a chelator. Acting like a chemical cage, the chelator securely holds the radioisotope in place and prevents it from separating during circulation. After the radiopharmaceutical is administered, usually through an intravenous infusion, it travels through the bloodstream until the carrier binds to its matching receptor on cancer cells. The tumor either absorbs the compound or retains it on its surface, allowing the attached radioisotope to continuously deliver localized radiation directly to the malignancy.
One of the earliest and most successful examples of radioisotope therapy is the use of Iodine-131 to treat thyroid disease. The thyroid gland naturally concentrates iodine from the bloodstream to produce thyroid hormones, and many thyroid cancer cells retain this ability. When patients swallow an Iodine-131 capsule, the isotope is selectively absorbed by remaining thyroid tissue and metastatic thyroid cancer cells. The beta particles emitted during radioactive decay destroy these abnormal cells while traveling only a short distance, limiting radiation exposure to nearby structures such as the vocal cords and parathyroid glands.
More recently, radioisotope therapy has become an important treatment for neuroendocrine tumors through Peptide Receptor Radionuclide Therapy (PRRT). These tumors commonly express large numbers of somatostatin receptors on their surfaces. By attaching Lutetium-177 to a synthetic peptide that binds specifically to these receptors, physicians can deliver targeted radiation to tumors located throughout the pancreas, abdomen, and lungs. This treatment has significantly improved progression-free survival for many patients with advanced neuroendocrine cancers who previously had few effective treatment options.
Another major advance has occurred in the treatment of advanced prostate cancer by targeting Prostate-Specific Membrane Antigen (PSMA), a protein found in high concentrations on prostate cancer cells. Lutetium-177 can be linked to a small molecule that selectively binds to PSMA, allowing radiation to reach metastatic tumors throughout the bones and soft tissues. This targeted approach reduces tumor burden, relieves cancer-related bone pain, and limits radiation exposure to healthy organs, including much of the bone marrow.
Radioisotope therapy has also led to the development of an innovative approach known as theranostics, a term that combines therapy and diagnostics. Because the targeting molecule remains the same, physicians can substitute a diagnostic isotope for a therapeutic one. For example, a patient may first receive a radiopharmaceutical labeled with Gallium-68, a positron-emitting isotope used for PET imaging. The resulting scan shows exactly where the drug accumulates, confirming that the cancer cells express the appropriate target. If significant uptake is demonstrated, the Gallium-68 is replaced with Lutetium-177 for treatment, providing confidence that the therapeutic radiation will reach the intended tumor sites.
Delivering radioisotope therapy requires close collaboration among nuclear medicine physicians, medical oncologists, medical physicists, pharmacists, and radiation safety specialists. Because patients temporarily become radioactive following treatment, strict safety protocols protect both patients and those around them. Depending on the isotope and treatment dose, therapy may be performed on an outpatient basis or require admission to a specially designed, lead-shielded hospital room.
During the days following treatment, unbound radiopharmaceuticals are naturally eliminated through the body’s excretory system, primarily in the urine. Patients receive detailed instructions regarding radiation safety, including flushing the toilet multiple times after use, sleeping separately from partners, limiting close contact with young children and pregnant women, and following these precautions until radiation levels decline to safe limits.
As molecular biology continues identifying new cancer-specific biomarkers and nuclear science develops increasingly effective alpha- and beta-emitting isotopes, the future of radioisotope therapy continues to expand. This remarkable combination of physics, chemistry, and medicine has transformed radiation from an external treatment into an intelligent, targeted therapy capable of locating and destroying cancer cells with extraordinary precision. It represents one of the most promising advances in modern oncology, offering patients increasingly personalized treatments while preserving more healthy tissue than ever before.
Comprehensive Cancer Centers Can Help
Physicians at Comprehensive Cancer Centers provide a variety of treatment options for cancers and other illnesses, with treatments, such as radioisotope therapy, being conducted in Southern Nevada. To schedule an appointment, please call 702-952-3350.
The content in this post is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of qualified health providers with questions you may have regarding medical conditions.